Bioactive Compound Produced from Actinomycetes- Streptomyces

Parisa Azerang and Soroush Sardari
Additional contact information
Soroush Sardari: Drug Design and Bioinformatics Unit, Medical Biotechnology Department, Pasteur Institute of Iran, Tehran

Novel Approaches in Drug Designing & Development, 2017, vol. 1, issue 3, 52-53

Abstract: The beginning of antibiotic-resistance among the bacteria is really unavoidable. Over the last 60 years, bacteria and, in particular, those pathogenic for humans have evolved toward anti-microbial drug resistance. For the treatment of infectious diseases antibiotics like penicillin and erythromycin are used but now these antibiotics become less effective because bacteria have become more resistant to such antibiotics. The development of new antimicrobial agents is an urgent medical need. Natural products are important sources of lead antimicrobial agents. Actinomycetes are soil dwelling and Gram positive bacteria and industrially wide range of bioactive secondary metabolites producers, including many antibiotics. More than75% of antibiotics are sourced from the genus Streptomyces. This review article focuses on microbial secondary metabolites from Streptomyces as new drugs to fight against antibiotic resistance.

Keywords: juniper publishers; drug designing pdf; drug designing articles; drug designing abstract; drug designing journal; modern approaches in drug designing journal; drug designing & intellectual properties international journal; peer reviewed open access journals; high impact journals; juniper publishers review (search for similar items in EconPapers)
Date: 2017
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
https://juniperpublishers.com/napdd/pdf/NAPDD.MS.ID.555565.pdf (application/pdf)
https://juniperpublishers.com/napdd/NAPDD.MS.ID.555565.php (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:adp:jnapdd:v:1:y:2017:i:3:p:52-53

DOI: 10.19080/NAPDD.2017.01.555565

Access Statistics for this article

Novel Approaches in Drug Designing & Development is currently edited by Sophia Mathis

More articles in Novel Approaches in Drug Designing & Development from Juniper Publishers Inc.
Bibliographic data for series maintained by Robert Thomas ().